Kevin, you don't have enough data to make such a conclusion.
Probably not even sny can make such conclusion.
How would you account for patients currently taking Afrezza, but have not refilled yet?
In a small way, it's encouraging.
$6.00 buys a share. To take control they can not buy enough shares because,
1. It would push PPS to huge heights
2. There aren't enough shares available to get 51%
Wonder what the management thinks of their own performance?
Al Mann loves it because he rewards them handsomely.
I don't get it!
1. SNY would partner with mnkd years ago.
2. Was right on Adcom.
3. Was right on FDA approval.
4. SNY did partner.
Now he predicts BO by SNY.
My money with Kevin.
Institutions are buying currently.
PPS is on a up trend while shorts increased their hold.
The only way that could happen is when huge money is joining in.
Any day this epic covering going to start.
Shorts are risking monumental amounts of dollars to keep PPS from rising and yet the trend is pushing up. Shorts need to risk more and more dollars until they go broke. How will they pay to cover is a mystery.
If you build it and tell no one, no one will come.
I think mnkd and SNY were skeptical of Afrezza and mnkd ability to produce keeping up with demand.
Probably that would also provide tax advantages. Which is in millions.